Empagliflozin and Major Renal Outcomes in Heart Failure-Reference-Cited by-同舟云学术

Empagliflozin and Major Renal Outcomes in Heart Failure

Published:2021-10-14 Issue:16 Volume:385 Page:1531-1533
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Packer Milton¹^ORCID,Butler Javed²,Zannad Faiez³,Pocock Stuart J.⁴,Filippatos Gerasimos⁵,Ferreira João P.³,Brueckmann Martina⁶,Jamal Waheed⁶,Zeller Cordula⁷,Wanner Christoph⁸,Anker Stefan D.⁹

Affiliation:

1. Baylor University Medical Center, Dallas, TX

2. University of Mississippi School of Medicine, Jackson, MS

3. Université de Lorraine, Nancy, France

4. London School of Hygiene and Tropical Medicine, London, United Kingdom

5. National and Kapodistrian University of Athens School of Medicine, Athens, Greece

6. Boehringer Ingelheim, Ingelheim, Germany

7. Boehringer Ingelheim Pharma, Biberach, Germany

8. University Hospital of Würzburg, Würzburg, Germany

9. Charité Universitätsmedizin, Berlin, Germany

Funder

Boehringer Ingelheim

Eli Lilly and Company

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMc2112411

Cited by 96 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. DCRM 2.0: Multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases;Metabolism;2024-10

2. Distinct Comorbidity Clusters in Patients With Acute Heart Failure;JACC: Heart Failure;2024-07

3. A Case-Based Implementation of Heart Failure Therapies, A Consensus Pathway by The Saudi Heart Failure Working Group;Journal of the Saudi Heart Association;2024-06-01

4. Great Debate: SGLT2 inhibitors should be first-line treatment in heart failure with reduced ejection fraction;European Heart Journal;2024-05-28

5. Differences in presentation, diagnosis and management of heart failure in women. A scientific statement of the Heart Failure Association of the ESC;European Journal of Heart Failure;2024-05-23